Introduction

A government ethics watchdog has formally asked federal investigators to examine whether a senior health official violated conflict-of-interest rules. The complaint targets the director of the Advanced Research Projects Agency for Health and focuses on her public support for a hormone therapy policy change while she held financial interests in related businesses.

What Happened

The Campaign Legal Center sent a letter to the Department of Health and Human Services inspector general requesting a review of Alicia Jackson, who leads ARPA-H. The request follows reporting that found Jackson backed the removal of 'black box' warnings from hormone replacement therapy products while owning shares in Evernow, a company she founded that connects patients with menopause treatments. Her financial disclosures show she held at least $115,000 in Evernow stock, along with an undisclosed number of stock options.

The watchdog also questioned whether Jackson fully disclosed assets tied to her husband's investment firm, 137 Ventures, including as much as $400 million in underlying holdings. Reviewers identified at least one fund managed by the firm that invested in Thirty Madison, a virtual care company with a subsidiary offering hormone treatments for menopause. Jackson's disclosures do not indicate she sold her stake in that fund before the warning-label announcement.

It remains unclear what specific role, if any, she played in the decision to eliminate the warning requirement. Jackson has been placed on administrative leave, though HHS has not publicly explained why. Neither she nor the department has said whether she secured an ethics waiver before taking part in the policy announcement.

Why This Matters

Federal ethics rules restrict government employees from participating in matters that could affect their own finances. Ethics experts have said that speaking at a press conference or appearing in a news release can count as participation, even if the official did not cast the deciding vote.

The case also highlights concerns about the financial disclosure process. Jackson's two most recent disclosure forms have not been certified by ethics staff, despite a legal requirement that such forms be reviewed for compliance. If companies connected to the undisclosed funds received agency contracts or grants, experts say the conflicts could be significant.

Key Takeaways

  • A nonpartisan ethics group has asked the HHS inspector general to investigate ARPA-H Director Alicia Jackson.
  • The complaint alleges she supported a hormone therapy policy change while owning stock in Evernow, a menopause treatment company she founded.
  • Watchdog reviewers also flagged potential ties between her husband's investment firm and businesses involved in hormone care.
  • Jackson's financial disclosures remain uncertified, and HHS has not said whether she obtained an ethics waiver.
  • She is currently on administrative leave without a public explanation from the department.

Conclusion

The inspector general's office has not confirmed whether it has opened an investigation. Until more information emerges, the case underscores the importance of transparency and recusal when federal officials shape policies that intersect with their personal investments. For now, Jackson remains on leave as the agency says it is reviewing the situation.